ArticlePloS one2018
Off-label use of ceftiofur in one-day chicks triggers a short-term increase of ESBL-producing E. coli in the gut.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Distribution and characteristics of ceftiofur-resistant Escherichia coli throughout the broiler production chain in Korea.Veterinary research · 2026Article
- Co-Occurrence and Molecular Characterization of ESBL-Producing and Colistin-ResistantFoods (Basel, Switzerland) · 2025Article
- Effective Control ofAntibiotics (Basel, Switzerland) · 2025Article
- Serogrouping and Molecular Characterization of ESBL-Producing Avian PathogenicAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Article
- Pathological and pharmacovigilance monitoring as toxicological imputations of azithromycin and its residues in broilers.Veterinary world · 2024Article
- Antimicrobial resistance: One Health approach.Veterinary world · 2022Review
- Antimicrobial resistance in the globalized food chain: a One Health perspective applied to the poultry industry.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Increased Salmonella Schwarzengrund prevalence and antimicrobial susceptibility of Salmonella enterica isolated from broiler chickens in Kagoshima Prefecture in Japan between 2013 and 2016.The Journal of veterinary medical science · 2020Article
- Antimicrobial Resistance in Farm Animals in Brazil: An Update Overview.Animals : an open access journal from MDPI · 2020Review
- Eight years of sales surveillance of antimicrobials for veterinary use in Germany-What are the perceptions?PloS one · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This trial was designed to evaluate the off-label use of ceftiofur with Marek's vaccine in one-day-old broiler chicks, a prophylactic treatment that has been done in some commercial hatcheries, on the emergence of extended-spectrum beta-lactamase producing Escherichia coli (ESBL-E. coli). A total of 168 chicks (Cobb500®) were used in a completely randomized design. Birds were assigned to two treatments (Marek's vaccine plus saline vs Marek's vaccine plus ceftiofur) and six repetitions, with 14 animals each. Cloacal swabs were collected from 1 to 14 days post-hatch. The majority (86%; p<0.0001) of the ESBL-producing isolates harboring blaCTX-M and blaSHV genes originated from animals receiving the antimicrobial. None of the isolates were positive for plasmid-mediated AmpC betalactamase genes (blaACC, blaCMY-2, blaDHA, blaFOX, blaMOX and blaMIR). These findings indicate that the off-label use of ceftiofur with Marek's vaccine is associated with the short-term increase in ESBL-producing Escherichia coli in the gut of chicks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.